Wetenschappelijke publicaties van Bordet

Iron-deficiency anemia evaluation and treatment in hospitalized cancer patients: a feasibility study.

Meyers M, Paesmans M, Fleur W, Libert I, Klášterský J

Iron-deficiency anemia evaluation and treatment in hospitalized cancer patients: a feasibility study.

Meyers M, Paesmans M, Fleur W, Libert I, Klášterský J

Iron-deficiency anemia evaluation and treatment in hospitalized cancer patients: a feasibility study.

Adolescent Engagement With a Multicomponent mHealth Tool: Identifying Usage Patterns, Determinants, and Health Behavior Change in an Intervention Trial.

Peuters C, DeSmet A, Maenhout L, Cardon G, Debeer D, Crombez G

Adolescent Engagement With a Multicomponent mHealth Tool: Identifying Usage Patterns, Determinants, and Health Behavior Change in an Intervention Trial.

Brain imaging screening in metastatic breast cancer: patients' and physicians' perspectives.

Matos L, van Ramshorst M, Müller V, Agostinetto E, Linn S, Lambertini M, Dieras V, le Du F, Braga S, Criscitiello C, Jerzak KJ, Morgan G, Brucker S, von Kroge P, Haidinger R, Rodríguez Recio G, Schumacher-Wulf E, Fontes Sousa M, Schettini F, Laakmann E

Brain imaging screening in metastatic breast cancer: patients' and physicians' perspectives.

Gallbladder Volvulus: A Rare Entity with \"Beak Sign\" and \"Whirl Sign\".

Vlasselaer M, Pezzullo M, Liberale G

Gallbladder Volvulus: A Rare Entity with \"Beak Sign\" and \"Whirl Sign\".

Randomised trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer: a study protocol of ARIADNE.

Matikas A, Naume B, Wildiers H, Sonke G, Dieci MV, Karakatsanis A, Andersson A, Barnekow E, Kessler LE, Einbeigi Z, Killander F, Linderholm B, Schiza A, Valachis A, Nearchou A, Engebraaten O, Porojnicu A, Soland MH, Mannsåker B, Raj SX, Blix ES, Nordstrand CS, Lambertini M, Vernieri C, Punie K, Sotiriou C, Bergh J, Villacampa G, Zouzos A, Hellström M, Hartman J, Foukakis T

Randomised trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer: a study protocol of ARIADNE.

Managing relapses during or after adjuvant CDK4/6 inhibitors in HR-positive/HER2-negative early breast cancer: an emerging challenge.

Gerosa R, Gentile G, Arecco L, Dauccia C, Nannini S, Lobo-Martins S, Agostinetto E, Lambertini M, Santoro A, Aftimos P, Piccart-Gebhart M, de Azambuja E

Managing relapses during or after adjuvant CDK4/6 inhibitors in HR-positive/HER2-negative early breast cancer: an emerging challenge.

Gerosa R, Gentile G, Arecco L, Dauccia C, Nannini S, Lobo-Martins S, Agostinetto E, Lambertini M, Santoro A, Aftimos P, Piccart-Gebhart M, de Azambuja E

Managing relapses during or after adjuvant CDK4/6 inhibitors in HR-positive/HER2-negative early breast cancer: an emerging challenge.

Gerosa R, Gentile G, Arecco L, Dauccia C, Nannini S, Lobo-Martins S, Agostinetto E, Lambertini M, Santoro A, Aftimos P, Piccart-Gebhart M, de Azambuja E

Managing relapses during or after adjuvant CDK4/6 inhibitors in HR-positive/HER2-negative early breast cancer: an emerging challenge.

Erasmusziekenhuis

Bekijk alle wetenschappelijke publicaties van Erasmus

Wetenschappelijke publicaties van Erasmus

Queen Fabiola Kinderziekenhuis

Bekijk alle wetenschappelijke publicaties van het Koningin Fabiola Kinderziekenhuis

Wetenschappelijke publicaties van het Koningin Fabiola-Kinderziekenhuis

Jules Bordet-instituut

Bekijk alle wetenschappelijke publicaties van Jules Bordet

Wetenschappelijke publicaties van Jules Bordet

Wetenschappelijke publicaties van Bordet